ProPhase Labs Long Term Debt 2010-2024 | PRPH

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ProPhase Labs long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ProPhase Labs long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$79.2B
Takeda Pharmaceutical (TAK)	$43.3B
Sandoz Group AG (SDZNY)	$19.5B
Merck (MKKGY)	$19.2B
Astellas Pharma (ALPMY)	$18.2B
United Therapeutics (UTHR)	$16.1B
Summit Therapeutics (SMMT)	$14.7B
Neurocrine Biosciences (NBIX)	$12.1B
Shionogi (SGIOY)	$11.9B
Catalent (CTLT)	$10.7B
Jazz Pharmaceuticals (JAZZ)	$7.1B
Madrigal Pharmaceuticals (MDGL)	$6.9B
Orion OYJ (ORINY)	$6.7B
Corcept Therapeutics (CORT)	$5.7B
Ionis Pharmaceuticals (IONS)	$5.3B
Crinetics Pharmaceuticals (CRNX)	$5.1B
PTC Therapeutics (PTCT)	$3B
Dyne Therapeutics (DYN)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Arrowhead Pharmaceuticals (ARWR)	$2.3B
Soleno Therapeutics (SLNO)	$2.2B
NewAmsterdam Pharma (NAMS)	$2.2B
Centessa Pharmaceuticals (CNTA)	$1.9B
Evotec AG (EVO)	$1.8B
Recursion Pharmaceuticals (RXRX)	$1.8B
Xencor (XNCR)	$1.7B
BioCryst Pharmaceuticals (BCRX)	$1.5B
Indivior (INDV)	$1.4B
Harrow (HROW)	$1.4B